Norges Bank Ultragenyx Pharmaceutical Inc. Transaction History

Norges Bank

$716 Trillion
Q3 2024

49 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$37.42 - $51.61 $37.5 Million - $51.7 Million	1,002,463 New	1,002,463 $41.2 Million
Q4 2023 Feb 09, 2024	BUY	$31.73 - $49.19 $24.4 Million - $37.9 Million	770,506 New	770,506 $36.8 Million
Q3 2023 Nov 13, 2024	BUY	$34.92 - $46.66 $20.9 Million - $27.9 Million	598,088 New	598,088 $21.3 Million
Q3 2023 Nov 13, 2023	SELL	$34.92 - $46.66 $26.7 Million - $35.7 Million	-765,120 Closed	0 $0
Q2 2023 Aug 14, 2024	SELL	$37.35 - $52.15 $15.1 Million - $21.1 Million	-404,375 Reduced 40.34%	598,088 $27.6 Million
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $25 Million - $34.9 Million	-669,270 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$36.99 - $48.71 $24.9 Million - $32.8 Million	673,692 New	673,692 $27 Million
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $24.4 Million - $33.5 Million	723,632 New	723,632 $33.5 Million
Q3 2022 Nov 13, 2023	BUY	$39.96 - $66.14 $30.6 Million - $50.6 Million	765,120 New	765,120 $31.7 Million
Q2 2022 Aug 14, 2023	BUY	$45.8 - $85.4 $30.7 Million - $57.2 Million	669,270 New	669,270 $39.9 Million
Q1 2022 May 12, 2023	SELL	$62.2 - $84.4 $3.79 Million - $5.14 Million	-60,956 Reduced 8.42%	662,676 $48.1 Million
Q1 2022 May 09, 2022	SELL	$62.2 - $84.4 $38.7 Million - $52.5 Million	-621,576 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$73.71 - $87.86 $45.8 Million - $54.6 Million	621,576 New	621,576 $52.3 Million
Q3 2021 Nov 14, 2022	BUY	$77.92 - $102.4 $43.8 Million - $57.6 Million	562,538 New	562,538 $50.7 Million
Q3 2021 Nov 05, 2021	SELL	$77.92 - $102.4 $47.1 Million - $61.9 Million	-604,338 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$92.19 - $115.71 $55.7 Million - $69.9 Million	604,338 New	604,338 $57.6 Million
Q2 2021 Aug 10, 2021	SELL	$92.19 - $115.71 $50.2 Million - $63 Million	-544,453 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$106.9 - $167.73 $58.2 Million - $91.3 Million	544,453 New	544,453 $62 Million
Q1 2021 May 07, 2021	SELL	$106.9 - $167.73 $59.8 Million - $93.8 Million	-559,443 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$84.4 - $177.39 $47.2 Million - $99.2 Million	559,443 New	559,443 $77.4 Million
Q4 2020 Feb 10, 2021	SELL	$84.4 - $177.39 $40.1 Million - $84.2 Million	-474,822 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$72.98 - $90.0 $34.7 Million - $42.7 Million	474,822 New	474,822 $39 Million
Q3 2020 Nov 10, 2020	SELL	$72.98 - $90.0 $34.7 Million - $42.8 Million	-475,354 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$46.91 - $78.22 $22.3 Million - $37.2 Million	475,354 New	475,354 $37.2 Million
Q2 2020 Aug 07, 2020	SELL	$46.91 - $78.22 $24 Million - $40.1 Million	-512,564 Closed	0 $0
Q1 2020 May 07, 2021	BUY	$33.8 - $62.9 $17.3 Million - $32.2 Million	512,564 New	512,564 $22.8 Million
Q1 2020 May 08, 2020	SELL	$33.8 - $62.9 $17.3 Million - $32.2 Million	-512,564 Closed	0 $0
Q4 2019 Mar 03, 2020	BUY	$36.08 - $45.83 $18.5 Million - $23.5 Million	512,564 New	512,564 $21.9 Million
Q4 2019 Feb 12, 2020	SELL	$36.08 - $45.83 $18.5 Million - $23.5 Million	-512,564 Closed	0 $0
Q3 2019 Nov 13, 2020	BUY	$42.5 - $63.11 $21.8 Million - $32.3 Million	512,564 New	512,564 $21.9 Million
Q3 2019 Nov 08, 2019	SELL	$42.5 - $63.11 $20.6 Million - $30.6 Million	-484,506 Closed	0 $0
Q2 2019 Aug 13, 2020	BUY	$54.93 - $74.36 $26.6 Million - $36 Million	484,506 New	484,506 $30.8 Million
Q2 2019 Aug 09, 2019	SELL	$54.93 - $74.36 $24.2 Million - $32.8 Million	-440,507 Closed	0 $0
Q1 2019 May 11, 2020	BUY	$39.87 - $69.36 $2.85 Million - $4.95 Million	71,429 Added 19.35%	440,507 $30.6 Million
Q4 2018 Mar 04, 2019	BUY	$38.89 - $77.3 $14.4 Million - $28.5 Million	369,078 New	369,078 $16 Million
Q4 2018 Feb 08, 2019	SELL	$38.89 - $77.3 $12.7 Million - $25.2 Million	-325,514 Closed	0 $0
Q3 2018 Nov 12, 2019	BUY	$71.81 - $90.15 $23.4 Million - $29.3 Million	325,514 New	325,514 $24.9 Million
Q3 2018 Nov 09, 2018	SELL	$71.81 - $90.15 $40 Million - $50.2 Million	-556,394 Closed	0 $0
Q2 2018 Aug 12, 2019	BUY	$48.54 - $85.31 $27 Million - $47.5 Million	556,394 New	556,394 $42.8 Million
Q2 2018 Jul 23, 2018	SELL	$48.54 - $85.31 $41.4 Million - $72.7 Million	-852,253 Closed	0 $0
Q1 2018 May 15, 2019	BUY	$44.33 - $58.52 $37.8 Million - $49.9 Million	852,253 New	852,253 $43.5 Million
Q1 2018 May 09, 2018	SELL	$44.33 - $58.52 $23.4 Million - $30.9 Million	-528,530 Closed	0 $0
Q4 2017 Mar 05, 2018	BUY	$43.54 - $57.32 $23 Million - $30.3 Million	528,530 New	528,530 $24.5 Million
Q4 2017 Feb 09, 2018	SELL	$43.54 - $57.32 $23 Million - $30.3 Million	-528,530 Closed	0 $0
Q3 2017 Nov 13, 2018	BUY	$49.79 - $66.32 $26.3 Million - $35.1 Million	528,530 New	528,530 $28.2 Million
Q3 2017 Nov 07, 2017	SELL	$49.79 - $66.32 $26.3 Million - $35.1 Million	-528,530 Closed	0 $0
Q2 2017 Jul 24, 2018	BUY	N/A	79,815 Added 17.79%	528,530 $32.8 Million
Q1 2017 May 11, 2018	SELL	N/A	-73,500 Reduced 14.07%	448,715 $30.4 Million
Q3 2016 Nov 13, 2017	BUY	N/A	522,215	522,215 $0

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.5M

Call Options Held

520K

Put Options Held

406K

Vanguard Group Inc Valley Forge, PA

9.95M
Shares

$446 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.6M
Shares

$251 Million
0.01% of portfolio
Sands Capital Management, LLC Arlington, VA

5.12M
Shares

$230 Million
0.91% of portfolio
Wellington Management Group LLP Boston, MA

4.17M
Shares

$187 Million
0.04% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.07M
Shares

$138 Million
0.02% of portfolio

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account